Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 113
Filter
Add more filters

Publication year range
1.
Opt Lett ; 47(7): 1806-1809, 2022 Apr 01.
Article in English | MEDLINE | ID: mdl-35363740

ABSTRACT

We demonstrate the crystal phase-selective synthesis for lead-free cesium manganese bromine perovskite nanocrystals synthesized by the modified hot-injection method due to changing the concentration of solvent (trioctylphosphine; TOP). The compositions synthesized were determined by the amount of TOP solvent, and the structure phase of the nanocrystals was selected from hexagonal CsMnBr3 to tetragonal Cs3MnBr5 as the amount of TOP solvent increased. The emission peaks of CsMnBr3 and Cs3MnBr5 nanocrystals were observed at 650 nm (red) and 520 nm (green), respectively. After a durability test at 85°C and 85% humidity for 24 h, the lead-free perovskite CsMnBr3 nanocrystal powder maintained its initial emission intensity, and the metal halide Cs3MnBr5 nanocrystal powder exhibited an increase in red emission due to the post-synthesis of CsMnBr3 nanocrystals.

2.
Br J Clin Pharmacol ; 87(11): 4323-4333, 2021 11.
Article in English | MEDLINE | ID: mdl-33822406

ABSTRACT

AIMS: To evaluate pharmacokinetic equivalence and preliminary safety of the adalimumab biosimilar CT-P17 administered via autoinjector (CT-P17 AI) or prefilled syringe (CT-P17 PFS) in healthy subjects. METHODS: This phase I, open-label study (ClinicalTrials.gov: NCT04295356) randomised subjects (1:1) to receive a single 40-mg (100 mg/mL) dose of CT-P17 AI or CT-P17 PFS. Primary endpoint was pharmacokinetic equivalence of CT-P17 AI to CT-P17 PFS for: area under the concentration-time curve from time zero to infinity (AUC0-inf ); area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last ); maximum serum concentration (Cmax ). Equivalence was determined if the 90% confidence interval for the geometric least-squares mean ratio was within the 80-125% equivalence margin. Additional pharmacokinetic endpoints, safety and immunogenicity were evaluated. RESULTS: Of 193 subjects who were randomised (98 CT-P17 AI; 95 CT-P17 PFS), 180 received study drug. Pharmacokinetic equivalence was demonstrated: 90% confidence intervals were within the 80-125% equivalence margin (AUC0-inf : 93.98-114.29; AUC0-last : 91.09-121.86; Cmax : 94.08-111.90). Mean serum CT-P17 concentrations, secondary pharmacokinetic parameters and numbers of subjects with antidrug antibodies (ADAs) or neutralising ADAs were comparable between groups. AUC0-inf , AUC0-last and Cmax were numerically lower for ADA-positive than for ADA-negative subjects (both groups); pharmacokinetic equivalence was also demonstrated among ADA-positive subjects. CT-P17 AI and CT-P17 PFS were well tolerated, with comparable overall safety profiles. CONCLUSIONS: CT-P17 AI and CT-P17 PFS were pharmacokinetically equivalent. Overall safety and immunogenicity were comparable between the 2 delivery devices.


Subject(s)
Biosimilar Pharmaceuticals , Adalimumab/adverse effects , Area Under Curve , Biosimilar Pharmaceuticals/adverse effects , Healthy Volunteers , Humans , Syringes , Therapeutic Equivalency , Tomography, X-Ray Computed
3.
J Med Virol ; 92(12): 2946-2954, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32073159

ABSTRACT

Human metapneumovirus (HMPV) is a leading cause of lower respiratory tract infection (LRTI) in pediatric and geriatric populations. We recently found that two PDZ-binding motifs of the M2-2 protein, 29-DEMI-32 and 39-KEALSDGI-46, play a significant role in mediating HMPV immune evasion in airway epithelial cells (AECs). However, their role in the overall pulmonary responses to HMPV infection has not been investigated. In this study, we found that two recombinant HMPVs (rHMPV) lacking the individual M2-2 PDZ-binding motif are attenuated in mouse lungs. Mice infected with mutants produce more cytokines/chemokines in bronchoalveolar lavage (BAL) fluid compared to mice infected with wild-type rHMPV. In addition, both mutants are able to enhance the pulmonary recruitment of dendritic cells (DCs) and T cells and induce effective protections against the HMPV challenge. The DC maturation is also significantly improved by the motif mutation. Taken together, our data provide proof-of-principle for two live-attenuated M2-2 mutants to be promising HMPV vaccine candidates that are effective in inducing higher pulmonary innate immunity and generating protection against HMPV infection.

4.
J Korean Med Sci ; 35(33): e279, 2020 Aug 24.
Article in English | MEDLINE | ID: mdl-32830468

ABSTRACT

BACKGROUND: Hereditary hemolytic anemia (HHA) is a rare disease characterized by premature red blood cell (RBC) destruction due to intrinsic RBC defects. The RBC Disorder Working Party of the Korean Society of Hematology established and updated the standard operating procedure for making an accurate diagnosis of HHA since 2007. The aim of this study was to investigate a nationwide epidemiology of Korean HHA. METHODS: We collected the data of a newly diagnosed pediatric HHA cohort (2007-2016) and compared this cohort's characteristics with those of a previously surveyed pediatric HHA cohort (1997-2006) in Korea. Each participant's information was retrospectively collected by a questionnaire survey. RESULTS: A total of 369 children with HHA from 38 hospitals distributed in 16 of 17 districts of Korea were investigated. RBC membranopathies, hemoglobinopathies, RBC enzymopathies, and unknown etiologies accounted for 263 (71.3%), 59 (16.0%), 23 (6.2%), and 24 (6.5%) of the cases, respectively. Compared to the cohort from the previous decade, the proportions of hemoglobinopathies and RBC enzymopathies significantly increased (P < 0.001 and P = 0.008, respectively). Twenty-three of the 59 hemoglobinopathy patients had immigrant mothers, mostly from South-East Asia. CONCLUSION: In Korea, thalassemia traits have increased over the past 10 years, reflecting both increased awareness of this disease and increased international marriages. The enhanced recognition of RBC enzymopathies is due to advances in diagnostic technique; however, 6.5% of HHA patients still do not have a clear diagnosis. It is necessary to improve accessibility of diagnosing HHA.


Subject(s)
Anemia, Hemolytic, Congenital/epidemiology , Adolescent , Anemia, Hemolytic, Congenital/diagnosis , Anemia, Hemolytic, Congenital Nonspherocytic/diagnosis , Anemia, Hemolytic, Congenital Nonspherocytic/epidemiology , Child , Child, Preschool , Female , Glucosephosphate Dehydrogenase Deficiency/diagnosis , Glucosephosphate Dehydrogenase Deficiency/epidemiology , Hemoglobinopathies/diagnosis , Hemoglobinopathies/epidemiology , Hemoglobins/genetics , Hospitals , Humans , Infant , Infant, Newborn , Male , Polymorphism, Genetic , Pyruvate Kinase/deficiency , Pyruvate Metabolism, Inborn Errors/diagnosis , Pyruvate Metabolism, Inborn Errors/epidemiology , Republic of Korea/epidemiology , Retrospective Studies , Surveys and Questionnaires
5.
Int J Mol Sci ; 21(22)2020 Nov 20.
Article in English | MEDLINE | ID: mdl-33233493

ABSTRACT

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, the elderly, and immune-compromised patients. It is also a significant contributor to upper respiratory tract infection in the pediatric population. However, its disease mechanisms are still largely unknown. We have recently shown that a tRNA-derived RNA fragment (tRF) from the 5'-end of mature tRNA encoding GluCTC (tRF5-GluCTC), a recently discovered non-coding RNA, is functionally important for RSV replication and host gene regulation at the post-transcriptional level. However, how tRF5-GluCTC carries out the gene regulation is not fully known. In this study, we found that tRF5-GluCTC has impaired gene trans-silencing function in cells deficient of AGO1 or 4, while AGO2 and 3 seem not involved in tRF5-GluCTC-mediated gene regulation. By pulling down individual AGO protein, we discovered that tRF5-GluCTC is detectable only in the AGO4 complex, confirming the essential role of AGO4 in gene regulation and also suggesting that AGO1 contributes to the gene trans-silencing activity of tRF5-GluCTC in an atypical way. We also found that the P protein of RSV is associated with both AGO1 and 4 and AGO4 deficiency leads to reduced infectious viral particles. In summary, this study demonstrates the importance of AGO1 and 4 in mediating the gene trans-silencing function of tRF5-GluCTC.


Subject(s)
Argonaute Proteins/genetics , Eukaryotic Initiation Factors/genetics , Gene Silencing , RNA, Transfer/genetics , RNA, Untranslated/genetics , Respiratory Syncytial Virus, Human/genetics , A549 Cells , Argonaute Proteins/metabolism , Eukaryotic Initiation Factors/metabolism , Genes, Reporter , HEK293 Cells , Host-Pathogen Interactions/genetics , Humans , Luciferases/genetics , Luciferases/metabolism , RNA, Transfer/metabolism , RNA, Untranslated/metabolism , Respiratory Syncytial Virus, Human/metabolism , Signal Transduction , Viral Load , Viral Structural Proteins/genetics , Viral Structural Proteins/metabolism , Virus Replication
6.
Korean J Parasitol ; 58(3): 257-265, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32615739

ABSTRACT

The outbreak of human toxoplasmosis can be attributed to ingestion of food contaminated with Toxoplasma gondii. Toxoplasmosis recently increased in domestic and stray dogs and cats. It prompted studies on the zoonotic infectious diseases transmitted via these animals. Sero- and antigen prevalences of T. gondii in dogs and cats were surveyed using ELISA and PCR, and B1 gene phylogeny was analyzed in this study. Toxoplasmosis antibodies were measured on sera of 403 stray cats, 947 stray dogs, 909 domestic cats, and 2,412 domestic dogs collected at nationwide regions, Korea from 2017 to 2019. In addition, whole blood, feces, and tissue samples were also collected from stray cats (1,392), stray dogs (686), domestic cats (3,040), and domestic dogs (1,974), and T. gondii-specific B1 gene PCR was performed. Antibody prevalence of stray cats, stray dogs, domestic cats, and domestic dogs were 14.1%, 5.6%, 2.3%, and 0.04%, respectively. Antigen prevalence of these animals was 0.5%, 0.2%, 0.1%, and 0.4%, respectively. Stray cats revealed the highest infection rate of toxoplasmosis, followed by stray dogs, domestic cats, and domestic dogs. B1 gene positives were 5 of stray cats, and identified to high/moderate pathogenic Type I/III group. These findings enforce that preventive hygienic measure should be strengthened at One Health level in dogs and cats, domestic and stray, to minimize human toxoplasmosis infections.


Subject(s)
Cat Diseases/epidemiology , Cat Diseases/parasitology , Cats/parasitology , Dog Diseases/epidemiology , Dog Diseases/parasitology , Dogs/parasitology , Genes, Protozoan/genetics , Toxoplasma/genetics , Toxoplasmosis, Animal/parasitology , Animals , Phylogeny , Polymerase Chain Reaction , Republic of Korea/epidemiology , Seroepidemiologic Studies , Toxoplasmosis/parasitology , Toxoplasmosis/prevention & control
7.
J Virol ; 92(22)2018 11 15.
Article in English | MEDLINE | ID: mdl-30185593

ABSTRACT

Respiratory syncytial virus (RSV) is the leading cause of respiratory infection in young children and high-risk adults. However, a specific treatment for this viral infection is not currently available. In this study, we discovered that an exchange protein directly activated by cyclic AMP (EPAC) can serve as a potential therapeutic target for RSV. In both lower and upper epithelial cells, treatment with EPAC inhibitor (ESI-09), but not protein kinase A inhibitor (H89), significantly inhibits RSV replication and proinflammatory cytokine/chemokine induction. In addition, RSV-activated transcriptional factors belonging to the NF-κB and IRF families are also suppressed by ESI-09. Through isoform-specific gene knockdown, we found that EPAC2, but not EPAC1, plays a dominant role in controlling RSV replication and virus-induced host responses. Experiments using both EPAC2 knockout and EPAC2-specific inhibitor support such roles of EPAC2. Therefore, EPAC2 is a promising therapeutic target to regulate RSV replication and associated inflammation.IMPORTANCE RSV is a serious public health problem, as it is associated with bronchiolitis, pneumonia, and asthma exacerbations. Currently no effective treatment or vaccine is available, and many molecular mechanisms regarding RSV-induced lung disease are still significantly unknown. This project aims to elucidate an important and novel function of a protein, called EPAC2, in RSV replication and innate inflammatory responses. Our results should provide an important insight into the development of new pharmacologic strategies against RSV infection, thereby reducing RSV-associated morbidity and mortality.


Subject(s)
Guanine Nucleotide Exchange Factors/antagonists & inhibitors , Guanine Nucleotide Exchange Factors/genetics , Respiratory Syncytial Virus, Human/growth & development , Respiratory Syncytial Virus, Human/genetics , Virus Replication/physiology , A549 Cells , Animals , Cell Line , Chemokines/immunology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Humans , Hydrazones/pharmacology , Isoquinolines/pharmacology , Isoxazoles/pharmacology , Mice , NF-kappa B/antagonists & inhibitors , RNA Interference , RNA, Small Interfering/genetics , Respiratory Syncytial Virus Infections/virology , Sulfonamides/pharmacology
8.
Korean J Parasitol ; 57(1): 17-20, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30840794

ABSTRACT

A stray female cat of unknown age, presenting bright red watery diarrhea, was submitted to the Animal and Plant Quarantine Agency for diagnosis. In the small intestines extracted from the necropsied cat, numerous white oval-shaped organisms were firmly embedded in the mucosa and there was thickening of intestinal wall. Histopathological analysis revealed severe necrotizing enteritis, together with atrophied intestinal villi, exfoliated enterocytes, and parasitic worms. Recovered worms were identified as Pharyngostomum cordatum by morphological observation and genetic analysis. Although P. cordatum is known to occur widely in Korea, this is the first clinical description of an infection by P. cordatum causing severe feline enteritis.


Subject(s)
Cat Diseases/diagnosis , Cat Diseases/pathology , Diarrhea/veterinary , Enterocolitis, Necrotizing/veterinary , Trematoda/isolation & purification , Trematode Infections/veterinary , Animals , Cat Diseases/parasitology , Cats , Diarrhea/diagnosis , Diarrhea/parasitology , Diarrhea/pathology , Enterocolitis, Necrotizing/diagnosis , Enterocolitis, Necrotizing/parasitology , Enterocolitis, Necrotizing/pathology , Female , Histocytochemistry , Intestinal Mucosa/parasitology , Intestinal Mucosa/pathology , Intestine, Small/parasitology , Intestine, Small/pathology , Korea , Trematoda/anatomy & histology , Trematoda/genetics , Trematode Infections/diagnosis , Trematode Infections/parasitology , Trematode Infections/pathology
9.
Emerg Infect Dis ; 24(12): 2343-2347, 2018 12.
Article in English | MEDLINE | ID: mdl-30457524

ABSTRACT

In December 2016, highly pathogenic avian influenza (HPAI) infection with systemic pathologic lesions was found in cats in South Korea. Genetic analyses indicated that the feline isolates were similar to HPAI H5N6 viruses isolated in chicken farms nearby. This finding highlights the need for monitoring of domestic mammals during HPAI outbreaks.


Subject(s)
Cat Diseases/epidemiology , Cat Diseases/virology , Influenza A virus/genetics , Animals , Biopsy , Cat Diseases/diagnosis , Cats , Disease Outbreaks , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Influenza A virus/classification , Influenza A virus/pathogenicity , Lung/pathology , Lung/virology , Male , Phylogeny , RNA, Viral , Republic of Korea/epidemiology
10.
Virol J ; 15(1): 115, 2018 07 28.
Article in English | MEDLINE | ID: mdl-30055639

ABSTRACT

BACKGROUND: Bovine viral diarrhea virus (BVDV) causes significant economic losses worldwide in the cattle industry through decrease in productive performance and immunosuppression of animals in herds. Recent studies conducted by our group showed that mice can be infected with BVDV-1 by the oral route. The purpose of this study was to assess the clinical signs, hematological changes, histopathological lesions in lymphoid tissues, and the distribution of the viral antigen after oral inoculation with a Korean noncytopathic (ncp) BVDV-2 field isolate in mice. METHODS: Mice were orally administered a low or high dose of BVDV-2; blood and tissue samples were collected on days 2, 5, and 9 postinfection (pi). We monitored clinical signs, hematological changes, histopathological lesions, and tissue distribution of a viral antigen by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) and then compared these parameters with those in ncp BVDV-1 infections. RESULTS: None of the infected mice developed any clinical signs of the illness. Significant thrombocytopenia was found in both low- and high-dose-inoculated mice on day 2 pi. Leukopenia was apparent only in low-dose-inoculated mice on day 2 pi, whereas lymphopenia was not observed in any ncp BVDV-2-infected animal. Viral RNA was found in the spleen in of low- and high-dose-inoculated mice by RT-PCR. According to the results of IHC, the viral antigen was consistently detected in lymphocytes of bone marrow and spleen and less frequently in bronchus-associated lymphoid tissue (BALT), mesenteric lymph nodes, and Peyer's patches. Despite the antigen detection in BALT and mesenteric lymph nodes, histopathological lesions were not observed in these tissues. Lympholysis, infiltration by inflammatory cells, and increased numbers of megakaryocytes were seen in Peyer's patches, spleens, and bone marrow, respectively. In contrast to ncp BVDV-1 infection, lympholysis was found in the spleen of ncp BVDV-2-infected mice. These histopathological lesions were more severe in high-dose-inoculated mice than in low-dose-inoculated mice. CONCLUSIONS: Our results provide insight into the pathogenesis of ncp BVDV-2 infection in mice. Collectively, these results highlight significant differences in pathogenesis between ncp BVDV-1 and ncp BVDV-2 infections in a murine model.


Subject(s)
Bone Marrow/pathology , Diarrhea Virus 2, Bovine Viral/physiology , Megakaryocytes/pathology , Megakaryocytes/virology , Pestivirus Infections/pathology , Pestivirus Infections/virology , Animals , Cattle , Disease Models, Animal , Hemorrhagic Syndrome, Bovine/blood , Hemorrhagic Syndrome, Bovine/pathology , Hemorrhagic Syndrome, Bovine/virology , Mice , Pestivirus Infections/blood , Peyer's Patches/pathology , Peyer's Patches/virology , RNA, Viral , Spleen/pathology , Spleen/virology , Viral Load
11.
J Neurooncol ; 139(2): 281-291, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29730815

ABSTRACT

BACKGROUND: PD-L1 expression has been evaluated as a predictive biomarker for immunotherapy in numerous tumor types. However, very limited data are available in pediatric brain tumors. The aim of this study was to characterize PD-1 and PD-L1 expressions of four pediatric malignant brain tumors and gene expression profile. METHODS: This study included 89 pediatric patients receiving standard treatment at Seoul National University Children's Hospital and Seoul National University Bundang Hospital between 1990 and 2014: atypical teratoid/rhabdoid tumor (AT/RT) 20; ependymoma (EPN) 20; high grade glioma (HGG) 21; and medulloblastoma (MBL) 28. We performed immunohistochemistry assays for PD-1 and PD-L1. To characterize the gene expression, a custom immune-response focused gene panel was used. RESULTS: PD-1 expression was positive in 7 (35%) AT/RT, 7 (35%) EPN, 4 (19%) HGG, and 3 (11%) MBL patients. PD-L1 expression was positive in 8 (40%) AT/RT, 4 (20%) EPN, and 4 (19%) HGG; negative in all MBL patients. There was no statistically significant difference in the overall survival of PD-L1 positive patients. The gene expression analysis demonstrated differences in two clustering functional categories: cell-cell signaling and antigen presentation pathway. CONCLUSIONS: AT/RT, EPN, and HGG showed a relatively higher expression rate of PD-L1 (19-40%). This suggests these tumor types might be good candidates for PD-1 checkpoint blockade. We determined that gene expression may potentially serve as a molecular tool in predicting which patients will respond to immunotherapy. Further investigation is required to better understand the predictive and prognostic role of PD-L1 in pediatric brain tumors.


Subject(s)
B7-H1 Antigen/metabolism , Brain Neoplasms/immunology , Programmed Cell Death 1 Receptor/metabolism , Adolescent , Biomarkers, Tumor/metabolism , Brain/immunology , Brain/pathology , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Brain Neoplasms/therapy , Child , Child, Preschool , Ependymoma/immunology , Ependymoma/mortality , Ependymoma/pathology , Ependymoma/therapy , Female , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Glioma/immunology , Glioma/mortality , Glioma/pathology , Glioma/therapy , Humans , Infant , Male , RNA, Messenger/metabolism , Retrospective Studies , Rhabdoid Tumor/immunology , Rhabdoid Tumor/mortality , Rhabdoid Tumor/pathology , Rhabdoid Tumor/therapy , Survival Analysis , Teratoma/immunology , Teratoma/mortality , Teratoma/pathology , Teratoma/therapy
12.
Cell Mol Biol (Noisy-le-grand) ; 64(10): 20-27, 2018 Jul 30.
Article in English | MEDLINE | ID: mdl-30084791

ABSTRACT

Late-onset hypogonadism (LOH) is associated with advancing age and is caused by a deficiency in serum testosterone levels. The aim of this study was to examine the effect of a Dendropanax morbiferus H.Lév. leaf extract (DME) on LOH using TM3 cells and aging male rats as in vitro and in vivo models, respectively. The in vitro effects of DME on testosterone levels and 3ß-hydroxysteroid dehydrogenase (3ß-HSD) protein expression in TM3 cells were analyzed. In the in vivo experiments, DME was orally administered to rats at three doses (50, 100, and 200 mg/kg/day) for 4 weeks. DME significantly increased the testosterone levels and 3ß-HSD protein expression in TM3 cells. The DME groups showed significantly increased levels of androgenic hormones such as testosterone and dehydroepiandrosterone sulfate. The sex hormone-binding globulin production was significantly lower in the DME groups than that in the control group, while the neurohormone levels in the hypothalamic-pituitary-gonadal axis markedly increased. No significant differences were observed in the glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, and prostate-specific antigen levels among the DME and control groups. The triglyceride and low-density lipoprotein cholesterol levels were significantly lower, while the high-density lipoprotein cholesterol levels were significantly higher in the DME groups than those in the control group. The latency time in the rotarod, treadmill, and swimming tests increased with the DME treatment. Furthermore, the sperm counts in the epididymis markedly increased. These results suggest that DME can be effectively used to alleviate the symptoms of LOH.


Subject(s)
Araliaceae/chemistry , Hypogonadism/drug therapy , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Testosterone/metabolism , 17-Hydroxysteroid Dehydrogenases/analysis , 17-Hydroxysteroid Dehydrogenases/metabolism , Aging , Animals , Cell Line , Hypogonadism/blood , Hypogonadism/metabolism , Hypogonadism/pathology , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/metabolism , Hypothalamo-Hypophyseal System/pathology , Leydig Cells/drug effects , Leydig Cells/metabolism , Leydig Cells/pathology , Male , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rats , Rats, Sprague-Dawley , Testosterone/analysis , Testosterone/blood
13.
J Korean Med Sci ; 33(1): e5, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-29215814

ABSTRACT

BACKGROUND: New B-domain deleted third generation recombinant factor VIII (FVIII; GreenGene F™, beroctocog alfa) was launched in 2010. We determined safety and efficacy of GreenGene F™ during routine clinical practice in patients with hemophilia A over a period of 12 months. METHODS: From July 2010 to July 2014, a total of 136 hemophilia A patients were enrolled in a post-marketing surveillance (PMS) study. Among them, 134 patients were assessed for drug safety and 114 patients were analyzed for drug efficacy. Patients with differing hemophilia A severities and medical histories were monitored during 12 months of prophylactic and/or on-demand therapy. RESULTS: Among 134 patients evaluated, 85 (63.4%) had severe hemophilia. Ninety-two received a total of 1,266,077 units for prophylaxis, and 42 received 516,491 units for bleeding episodes. Three patients developed inhibitors. In 112 previously treated patients, one patient (0.9%) developed inhibitor after intensive FVIII treatment for surgery. Among 22 previously untreated patients, inhibitors were observed in 2 infants (9.1%). Overall, there were a total of 47 adverse events (other than inhibitors) of all types in 30 patients (22.4%), 11 in 10 patients (7.5%) of which were considered showing serious adverse events (SAEs); most of which were hemorrhages at different sites. None of the SAEs were judged as product related. An excellent/good efficacy rate of 91.3% for hemostasis and 89.4% for hemorrhage prevention was recorded. CONCLUSION: The results of this PMS study support the use of GreenGene F™ as safe and efficacious in hemorrhage prevention and treatment of hemophilia A. These results are consistent with the findings from previously published GreenGene F™ studies.


Subject(s)
Factor VIII/therapeutic use , Hemophilia A/drug therapy , Adolescent , Adult , Aged , Blood Coagulation Factor Inhibitors/metabolism , Child , Child, Preschool , Factor VIII/adverse effects , Factor VIII/genetics , Factor VIII/metabolism , Gastrointestinal Diseases/etiology , Hemophilia A/pathology , Hemorrhage/prevention & control , Humans , Infant , Male , Middle Aged , Product Surveillance, Postmarketing , Recombinant Proteins/adverse effects , Recombinant Proteins/biosynthesis , Recombinant Proteins/therapeutic use , Republic of Korea , Severity of Illness Index , Treatment Outcome , Young Adult
14.
Pediatr Hematol Oncol ; 35(4): 276-287, 2018 May.
Article in English | MEDLINE | ID: mdl-30633619

ABSTRACT

OBJECTIVES: We aimed to evaluate treatment outcomes of pediatric acute lymphoblastic leukemia (ALL) subgroups by risk-stratification, in the Yeungnam region of Korea. METHODS: We reviewed the courses of 409 newly diagnosed ALL patients from January 2004 to December 2013 in the Yeungnam region. RESULTS: All patients were classified into three risk groups: standard risk (SR, n=212), high risk (HR, n=153) and very high risk (VHR, n=44). The mean follow-up time was 73.6 ± 39.4 months. The 7-year event-free survival (EFS) and overall survival (OS) rates were 78.7 ± 2.1% and 86.8 ± 1.8%, respectively. Significant 7-year EFS and OS rates for SR (84.0 ± 2.7%, 93.7 ± 1.8%), HR (76.5 ± 3.5%, 82.1 ± 3.3%), and VHR (60.6 ± 7.5%, 69.9 ± 7.5%) were observed (P<0.001), respectively. Relapse occurred in 52 patients, and the cumulative 7-year incidence of relapse differed according to risk groups (SR vs. HR vs. VHR=12.6% vs. 14.0% vs. 29.6%, P=0.003).For the 46 relapsed patients who were treated, the 3-year EFS and OS were 42.3 ± 8.3%and 46.4± 8.4%. Among the 44 VHR patients, EFS was not significantly different between the chemotherapy-treated patients and those received hematopoietic stem cell transplantation (P=0.533). The 7-year EFS of the hyperleukocytosis subgroup (24 cases, 14 under 10 years of age)showed a tendency for better prognosis than that of the other VHR subgroups (P=0.178). CONCLUSION: Our results revealed improved outcomes in pediatric ALL patients with risk-stratified therapy. The hyperleukocytosis subgroup without any combined chromosomal abnormalities may respond favorably to chemotherapy alone after first complete remission.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Prognosis , Republic of Korea , Retrospective Studies , Risk Assessment , Treatment Outcome , Young Adult
15.
Comput Inform Nurs ; 36(10): 494-500, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30303486

ABSTRACT

The purpose of this study was to identify the relationship between acceptance intention toward a smartphone healthcare application and health-promoting behaviors among nursing students in order to propose a method to encourage nursing students' personal health management. Data were collected from June to July 2015 in two cities located in South Korea, targeting 450 nursing students. There was a weak positive relationship between acceptance intention toward a smartphone healthcare application and health-promoting behaviors (r = 0.281, P < .001). There were differences in health-promoting behaviors according to the level of acceptance intention toward a smartphone healthcare application: health-promoting behavior scores for the upper 50% of participants with higher intention scores (high-score group) were statistically higher than those for the lower 50% of participants (low-score group) (t = 4.247, P < .001). In the logistic regression, the high-score group had a greater likelihood of performing health-promoting behaviors (odds ratio, 2.260; P < .001, 95% confidence interval, 1.539-3.321). Health-promoting behaviors tended to increase among nursing students when the acceptance intention toward a smartphone healthcare application was high. To increase nursing students' intention to accept a smartphone healthcare application, it is necessary to develop applications featuring diverse, interesting health-related content suitable for their needs, so that they want to use these applications to promote health.


Subject(s)
Health Behavior , Intention , Mobile Applications/statistics & numerical data , Smartphone , Students, Nursing/psychology , Cross-Sectional Studies , Female , Humans , Male , Republic of Korea , Students, Nursing/statistics & numerical data , Surveys and Questionnaires , Young Adult
16.
Arch Virol ; 161(9): 2527-35, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27376375

ABSTRACT

Previously, our study showed that oral inoculation of mice with cytopathic (cp) bovine viral diarrhea virus (BVDV) led to lymphocyte depletion and increased numbers of megakaryocytes in the spleen as well as thrombocytopenia and lymphopenia. In the present study, to investigate the possible differences in the detection of viral antigen, histopathological lesions, and hematologic changes between non-cytopathic (ncp) BVDV1 and cp BVDV1, mice were orally administered low and high doses of ncp BVDV1 and were necropsied at days 0, 2, 5, and 9 postinfection (pi). None of the ncp BVDV1-infected mice exhibited clinical signs of illness, unlike those infected with cp BVDV1. Statistically significant thrombocytopenia was observed during ncp BVDV1 infection, and lymphopenia was found only in mice infected with a high dose at day 9 pi. Interestingly, ncp BVDV1 infection increased the numbers of basophils, eosinophils, neutrophils, and monocytes in some infected mice. Viral antigen was detected in the lymphocytes of the spleen, mesenteric lymph nodes, Peyer's patches, and bone marrow by immunohistochemistry. Lymphoid depletion was evident in the mesenteric lymph nodes of mice infected with a high dose and also found in the Peyer's patches of some infected mice. Infiltration of inflammatory cells, including neutrophils and monocytes, and an increased number of megakaryocytes were seen in the spleen. These results suggest that the distribution of viral antigens is not associated with the presence of histopathological lesions. Inflammatory cell infiltration was observed in the spleens as a result of viral replication and may be attributable to the host reaction to ncp BVDV1 infection. Together, these findings support the possibility that mice can be used as an animal model for BVDV infection.


Subject(s)
Diarrhea Virus 1, Bovine Viral/pathogenicity , Leukocytes/physiology , Pestivirus Infections/virology , Spleen/cytology , Animals , Mice , Mice, Inbred BALB C , Pestivirus Infections/pathology , Specific Pathogen-Free Organisms , Spleen/virology
17.
Appl Microbiol Biotechnol ; 99(10): 4387-96, 2015 May.
Article in English | MEDLINE | ID: mdl-25586586

ABSTRACT

The emergence of antibiotic resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) reminds us an urgent need to develop a new immune-modulating agent for preventing S. aureus infection. In this study, we found that herbal medicines, honokiol and magnolol, caused a significant cellular immune modulatory effect during S. aureus infection. In mouse macrophages, these compounds drove upregulation of an antioxidant effect in response to S. aureus, resulting in a dampened total cellular reactive oxygen species (ROS) production and decreased production of inflammatory cytokines/chemokines, whereas honokiol induced increased types I and III interferon messenger RNA (mRNA) expression levels in response to MSSA infection. Moreover, the internalization of S. aureus by human alveolar epithelial cells was inhibited by these compounds. Furthermore, honokiol and magnolol treatment promoted a delay in killing during MSSA infection in Caenorhabditis elegans, suggesting antimicrobial function in vivo. In conclusion, honokiol and magnolol may be considered as attractive immune-modulating treatment for S. aureus infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Biphenyl Compounds/pharmacology , Lignans/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Plant Extracts/pharmacology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/immunology , Staphylococcus aureus/drug effects , Animals , Caenorhabditis elegans , Cytokines/immunology , Humans , Macrophages/drug effects , Macrophages/immunology , Methicillin/pharmacology , Methicillin-Resistant Staphylococcus aureus/growth & development , Mice , Plants, Medicinal/chemistry , Staphylococcal Infections/microbiology , Staphylococcus aureus/growth & development
18.
Biosci Biotechnol Biochem ; 79(3): 475-83, 2015.
Article in English | MEDLINE | ID: mdl-25516242

ABSTRACT

In this study, we investigated antibacterial activities of 20 plant-derived natural compounds against Gram-negative enteric pathogens. We found that both flavonoids and non-flavonoids, including honokiol and magnolol, possess specific antibacterial activities against V. cholerae, but not against other species of Gram-negative bacterium which we tested. Using various antibacterial assays, we determined that there was a dose-dependent bactericidal and biofilm inhibitory activity of honokiol and magnolol against Vibrio cholerae. In addition to antibacterial activities, these molecules also induced an attenuating effect on reactive oxygen species (ROS) production and pro-inflammatory responses generated by macrophages in response to lipopolysaccharides (LPS). Additionally, Caenorhabditis elegans lethality assay revealed that honokiol and magnolol have an ability to extend a lifespan of V. cholerae-infected worms, contributing to prolonged survival of worms after lethal infection. Altogether, our data show for the first time that honokiol and magnolol may be considered as attractive protective or preventive food adjuncts for cholera.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Biological Products/pharmacology , Plant Extracts/pharmacology , Vibrio cholerae/drug effects , Animals , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Biofilms/drug effects , Biological Products/therapeutic use , Caenorhabditis elegans , Cholera/drug therapy , Food , Lipopolysaccharides/adverse effects , Macrophages/drug effects , Mice , Plant Extracts/therapeutic use , RAW 264.7 Cells , Vibrio cholerae/physiology
19.
J Korean Med Sci ; 30(1): 117, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25547180

ABSTRACT

[This corrects the article on p. 1482 in vol. 29, PMID: 25408578.].

20.
Apoptosis ; 19(4): 657-67, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24287941

ABSTRACT

Axin is a multifunctional protein that participates in many cellular events including Wnt signaling and cell fate determination. Aurora kinase inhibitor (AKI)-induced cell death and cell membrane rupture is facilitated in L929 cells expressing axin (L-axin cells) through the activation of poly ADP-ribose polymerase (PARP). We observed that caspase-2 activity is required for AKI-induced cell death. Inhibition of caspase-2 activity suppressed AKI-induced PARP activation and mitochondrial dysfunction, resulting in a decrease in AKI-induced cell death. When an axin mutant deleted for the glycogen synthase kinase 3ß (GSK3ß)-binding domain was expressed in L929 cells (L-ΔGSK cells), AKI-induced caspase-2 activation and cell death decreased. AKI treatment reduced the expression of a 32-kDa caspase-2 splicing variant (caspase-2S) in most L-axin cells, but not in L-ΔGSK cells. These results suggest that AKI-induced caspase-2 activation in L-axin cells might be due to a decrease in the expression of caspase-2S, which inhibits caspase-2 activity. In addition, AKI treatment failed to activate caspase-8 and treatment with necrostatin inhibited AKI-induced cell death in L-axin cells, suggesting that the absence of caspase-8 activation might favor necrotic cell death. Axin expression may facilitate AKI-induced caspase-2 activation followed by activation of PARP and initiation of the necrotic cell death pathway.


Subject(s)
Aurora Kinases/antagonists & inhibitors , Axin Protein/metabolism , Caspase 2/metabolism , Animals , Aurora Kinases/metabolism , Caspase 8/metabolism , Caspase Inhibitors/pharmacology , Cell Death/drug effects , Cell Line , Enzyme Activation , Mice , Necrosis , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL